Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life.
Eustachio NettisLuisa BrussinoVincenzo PatellaLaura BonzanoAikaterini DetorakiElisabetta Di LeoMaria Maddalena SirufoCristiano CarusoFabio Lodi RizziniMariaelisabetta ConteMona-Rita YacoubMassimo TriggianiErminia RidoloLuigi MacchiaGiovanni RollaRaffaele BrancaccioAmato De PaulisGiuseppe SpadaroDanilo Di BonaAngela Maria D'UggentoLia GinaldiFrancesco GaetaEleonora NuceraKliljeda JaubashiDanilo VillaltaLorenzo DagnaDomenico CiottaFrancesco PucciariniDiego BagnascoGiorgio CeliFulvia Chieco BianchiLorenzo CosmiMaria Teresa CostantinoMaria Angiola CrivellaroSimona D'AlòPietro Del BiondoStefano Del GiaccoMario Di GioacchinoLinda Di PietroElisabetta FaveroSebastiano GangemiGabriella GuarnieriEnrico HefflerMaria Stefania Leto BaroneCarla LombardoFrancesca LosaAndrea MatucciPaola Lucia MinciulloPaola ParronchiGiovanni PassalacquaStefano PucciOliviero RossiLorenzo SalvatiMichele SchiappoliGianenrico SennaAndrea VianelloAlessandra VultaggioYang BaoranCristoforo IncorvaiaGiorgio Walter CanonicaPublished in: Clinical and molecular allergy : CMA (2022)
These data suggest that dupilumab treatment in patients suffering from CRSwNP and associated comorbidities may be suitable. Such outcome, although confirmation by trials is warranted, suggests the possibility to treat different disorders with a single therapy, with favorable effects especially under the cost-effectiveness aspect.